Read More

After Initial Rejection, FDA Approves Ardelyx’s Kidney Disease-Related Drug

The FDA approved Ardelyx Inc's (NASDAQ: ARDX) Xphozah (tenapanor), the first and only phosphate absorption inhibitor, indicated to reduce serum phosphorus in adults with chronic kidney disease (CKD) on dialysis as add-on therapy in patients who have inadequate response to phosphate binders or

ARDX

Read More

Cautious Optimism For Bluebird Bio’s Sickle Cell Therapy: Analyst Sees Financial Challenges

Cantor Fitzgerald initiated coverage on Bluebird Bio Inc (NASDAQ: BLUE), saying sickle cell disorder (SCD) has been a hotbed of development for genetic medicines as the company's lovo-cel marches towards the U.S. market. 

BLUE